What is the current state of molecular profiling for colorectal cancer?
John Marshall, MD, PhD, Lombardi Comprehensive Cancer Center, Georgetown University, WA, comments on the importance of genomic testing and current pitfalls of their use in colorectal cancer. Whilst molecular profiling is crucial for determining who can receive certain therapies, such as ones targeting tumor mutational burden (TMB)-high colorectal cancer, access to such testing is less prevalent in Europe compared to America. Prof. Marshall additionally emphasizes the need for educating clinicians on precision medicine. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found